Summit Therapeutics Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing. Summit is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue.
Business context and strategy
Summit shifted its focus from anti-infectives to oncology following its license of ivonescimab from Akeso. Summit holds development and commercialization rights in the United States, Canada, Europe and Japan; Akeso retains rights elsewhere. Ivonescimab is an investigational PD-1/VEGF bispecific antibody.
Summit-sponsored Phase III studies are evaluating ivonescimab with chemotherapy in two NSCLC settings: HARMONi, for EGFR-mutated disease after a third-generation EGFR TKI, and HARMONi-3, in first-line metastatic squamous NSCLC. Both were enrolling at the report date. HARMONi enrollment was expected to complete in the second half of 2024; HARMONi-3 enrollment began in the fourth quarter of 2023, with additional site activations planned through early 2025.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue | $0 | $0.7 million |
| Research and development expense | $59.5 million | $52.0 million |
| In-process research and development expense | $520.9 million | $0 |
| General and administrative expense | $30.3 million | $26.7 million |
| Total operating expenses | $610.7 million | $87.2 million |
| Operating loss | $609.7 million | $72.1 million |
| Net loss | $614.9 million | $78.8 million |
| Basic and diluted net loss per share | $0.99 | $0.41 |
| Net cash used in operating activities | $76.8 million | $41.6 million |
| Net cash used in investing activities | $587.8 million | $0.6 million |
| Net cash provided by financing activities | $86.5 million | $620.2 million |
The $520.9 million in-process R&D charge principally reflects the Akeso license upfront consideration: $474.9 million paid in cash, $45.9 million fair value for 10 million shares issued, and transaction costs. The charge is a major reason the reported net loss rose sharply; it is not recurring product-development revenue or expense guidance.
At year-end, cash and cash equivalents were $71.4 million and short-term U.S. Treasury investments were $114.8 million, totaling $186.2 million. Working capital was approximately $169.3 million; accumulated deficit was $993.3 million. The company reported $100 million of related-party promissory notes outstanding, classified as long-term after a February 2024 amendment. The note matures April 1, 2025, with interest from February 17, 2024 at the greater of 12% or prime plus 3.5%, compounded quarterly. The company paid $10.7 million cash interest in 2023.
No operating margin is meaningful for a company with no product sales. The filing reports no material legal proceedings. The auditor gave an unqualified opinion on the financial statements but highlighted substantial doubt about Summit’s ability to continue as a going concern.
Material changes versus FY 2022
- Revenue fell to zero after the previously recognized Eurofarma license revenue was fully recognized in 2022.
- Research and development expense rose $7.5 million, with $31.0 million of oncology spending on ivonescimab, partly offset by cessation of ridinilazole and SMT-738 development activities.
- Other operating income fell from $14.4 million to $1.0 million, as BARDA and CARB-X funding and U.K. R&D tax-credit income declined.
- Summit raised $500 million gross in a 2023 rights offering, issuing 476.2 million shares at $1.05 per share. Year-end shares outstanding increased to 701.7 million from 211.1 million a year earlier.
- Cash and cash equivalents declined from $348.6 million to $71.4 million, while the company held $114.8 million of short-term investments at year-end. The prior-year balance included $300 million of restricted cash held for the Akeso transaction.
Outlook, risks and unusual items
- Funding and going concern: Management expected existing cash, investments and U.K. tax credits to fund operations into the first quarter of 2025, including ongoing trials, but had not secured the additional capital needed for operations and repayment of the $100 million note. Management and the auditor identified substantial doubt about continued operations. Further financing may dilute shareholders, increase debt, or require reduced or delayed development.
- Akeso obligations: Beyond the upfront payment, Akeso may receive up to $1.05 billion in regulatory milestones and $3.45 billion in commercial milestones, plus low-double-digit royalties on licensed-territory net sales. Summit says timing and likelihood of contingent payments cannot currently be estimated.
- Clinical execution: Ivonescimab remains investigational. Trial results, patient enrollment, regulatory approvals, safety, regional consistency of data, manufacturing and commercialization are uncertain. Akeso’s published Phase II results cited by Summit are not Summit Phase III results and do not establish efficacy or approval.
- Supply and China exposure: Akeso initially is the sole manufacturer of Summit’s required ivonescimab drug substance. Summit is pursuing technology transfer and potential second-source suppliers. Manufacturing, supply, export/import, geopolitical and U.S.-China trade risks could delay trials or commercialization.
- Portfolio changes: Summit terminated internal development and marketing activities for ridinilazole and ceased further investment in the Discuva platform; it is seeking partnership opportunities for SMT-738. The Discuva intangible asset was impaired by $8.5 million in 2022.
- Other commitments: Contractual commitments excluding leases and debt were estimated at $37.7 million at year-end, mostly due within one year; an additional $23.0 million of clinical-trial commitments was entered into through February 9, 2024. A new Miami headquarters lease signed in January 2024 carries approximately $5.1 million of payments over 64 months.
- Governance and dilution: Robert Duggan beneficially owned approximately 78.3% of the shares as of February 2024, giving him substantial voting control. The company has elected controlled-company exemptions from certain Nasdaq governance requirements.
Important facts for investors to verify
- Current cash runway, financing plans and ability to repay or refinance the $100 million related-party note before its April 2025 maturity.
- Progress against HARMONi and HARMONi-3 enrollment plans, trial timelines, endpoints and any updates to expected completion dates.
- Whether Akeso’s Phase II findings are confirmed in Summit’s Phase III trials, including safety and outcomes across regions.
- Progress on ivonescimab manufacturing technology transfer, second-source qualification and supply commitments with Akeso.
- The potential timing, probability and funding requirements of Akeso milestones, royalties and other license-related obligations.
- Share dilution from future equity financing, equity awards and any registered resales by significant shareholders.
- U.K. R&D tax-credit receipts, clinical-trial commitments and other changes that could shorten the stated cash runway.